HER2-Positive vs Triple-Negative Breast Cancer: What Your Pathology Report Is Actually Telling You
Your pathology report does more than confirm cancer — it identifies the molecular subtype that determines every treatment decision ahead of you. This guide explains the real difference between HER2-positive and triple-negative breast cancer: what each subtype means biologically, how their treatments diverge, and what the latest survival data actually shows for patients diagnosed today.
By Gaf Healthcare Editorial Team
2026-05-08
<!DOCTYPE html> <html lang="en"> <head> <meta charset="UTF-8"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <title>HER2-Positive vs Triple-Negative Breast Cancer: What Your Pathology Report Is Actually Telling You</title> <meta name="description" content="HER2-positive and triple-negative breast cancer require completely different treatments. Learn what your receptor status means, how each subtype is treated, and what survival data shows for patients today."> <link rel="preconnect" href="https://fonts.googleapis.com"> <link href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,600;1,400&family=Source+Sans+3:wght@400;500;600&display=swap" rel="stylesheet"> <style> , ::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
:root { --cream: #F5F2EB; --cream-dark: #EDE9DF; --green-dark: #1B5E3B; --green-mid: #2D7A52; --green-light: #EAF4EE; --green-border: #C2DFCC; --red-accent: #B84040; --red-bg: #FDF2F2; --amber: #B07A15; --text-primary: #1A1A18; --text-body: #2E2E2A; --text-muted: #6B6860; --text-green: #1B5E3B; --border-soft: #DDD9CF; }
body { font-family: 'Source Sans 3', sans-serif; background-color: var(--cream); color: var(--text-body); font-size: 18px; line-height: 1.75; -webkit-font-smoothing: antialiased; }
.page-wrap { max-width: 740px; margin: 0 auto; padding: 48px 24px 80px; }
.meta-tag { display: inline-block; font-size: 11px; font-weight: 600; letter-spacing: 0.12em; text-transform: uppercase; color: var(--text-green); background: var(--green-light); border: 1px solid var(--green-border); border-radius: 4px; padding: 3px 10px; margin-bottom: 18px; }
h1 { font-family: 'Lora', Georgia, serif; font-size: clamp(26px, 4vw, 38px); font-weight: 600; line-height: 1.25; color: var(--text-primary); margin-bottom: 18px; letter-spacing: -0.01em; }
.deck { font-size: 19px; line-height: 1.6; color: var(--text-muted); margin-bottom: 28px; border-bottom: 1px solid var(--border-soft); padding-bottom: 28px; }
/ ILLUSTRATION / .illustration-wrap { margin: 8px 0 36px; border-radius: 10px; overflow: hidden; border: 1px solid var(--border-soft); background: var(--cream-dark); } .illustration-wrap svg { display: block; width: 100%; } .img-caption { font-size: 13px; color: var(--text-muted); padding: 10px 16px 12px; border-top: 1px solid var(--border-soft); font-style: italic; line-height: 1.6; }
/ TOC / .toc-box { background: var(--cream-dark); border: 1px solid var(--border-soft); border-radius: 10px; padding: 20px 24px 24px; margin: 0 0 40px; } .toc-label { display: flex; align-items: center; gap: 8px; font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--text-muted); margin-bottom: 14px; } .toc-label::before { content: ""; display: inline-block; width: 14px; height: 14px; background: var(--border-soft); border-radius: 2px; } .toc-box ol { list-style: none; padding: 0; display: flex; flex-direction: column; gap: 8px; } .toc-box ol li a { color: var(--text-green); text-decoration: none; font-size: 16px; font-weight: 500; border-bottom: 1px solid transparent; transition: border-color 0.15s; } .toc-box ol li a:hover { border-color: var(--green-mid); }
/ PROSE — Google short-paragraph standard / .prose h2 { font-family: 'Lora', Georgia, serif; font-size: clamp(20px, 3vw, 26px); font-weight: 600; color: var(--text-primary); margin: 44px 0 6px; padding-bottom: 12px; border-bottom: 1px solid var(--border-soft); letter-spacing: -0.01em; }
.prose p { font-family: 'Lora', Georgia, serif; font-size: 18px; line-height: 1.82; color: var(--text-body); margin-bottom: 16px; max-width: 68ch; } .prose p strong { font-weight: 600; color: var(--text-primary); }
.prose p.impact { font-size: 19px; font-style: italic; color: var(--text-muted); border-left: 3px solid var(--green-mid); padding-left: 18px; margin: 24px 0; }
/ QUICK ANSWER / .quick-box { background: var(--green-light); border: 1.5px solid var(--green-border); border-radius: 10px; padding: 20px 24px 22px; margin: 20px 0 24px; } .quick-box .qa-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--amber); display: flex; align-items: center; gap: 6px; margin-bottom: 10px; } .quick-box .qa-label::before { content: "⚡"; font-size: 13px; } .quick-box .qa-question { font-family: 'Source Sans 3', sans-serif; font-weight: 600; font-size: 17px; color: var(--text-primary); margin-bottom: 10px; } .quick-box .qa-answer { font-family: 'Source Sans 3', sans-serif; font-size: 16px; line-height: 1.7; color: var(--text-body); } .quick-box .qa-answer strong { color: var(--text-primary); }
/ STAT STRIP / .stat-strip { display: grid; grid-template-columns: repeat(auto-fit, minmax(130px, 1fr)); border: 1px solid var(--border-soft); border-radius: 8px; overflow: hidden; margin: 18px 0 24px; } .stat-cell { padding: 16px 18px 18px; border-right: 1px solid var(--border-soft); } .stat-cell:last-child { border-right: none; } .stat-cell .stat-label { font-size: 10px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--text-muted); margin-bottom: 6px; } .stat-cell .stat-val { font-size: 28px; font-weight: 600; color: var(--green-mid); font-family: 'Source Sans 3', sans-serif; line-height: 1.1; }
/ CALLOUTS / .callout-red { border-left: 3px solid var(--red-accent); background: var(--red-bg); border-radius: 0 8px 8px 0; padding: 16px 20px 18px; margin: 20px 0; } .callout-red .callout-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--red-accent); margin-bottom: 8px; } .callout-green { border-left: 3px solid var(--green-mid); background: var(--green-light); border-radius: 0 8px 8px 0; padding: 16px 20px 18px; margin: 20px 0; } .callout-green .callout-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--text-green); margin-bottom: 8px; } .callout-red p, .callout-green p { font-size: 16px; line-height: 1.7; font-family: 'Source Sans 3', sans-serif; color: var(--text-body); margin: 0; max-width: none; }
/ COMPARE TABLE / .compare-table { width: 100%; border-collapse: collapse; border: 1px solid var(--border-soft); border-radius: 8px; overflow: hidden; margin: 18px 0 24px; font-size: 15px; } .compare-table thead th { background: var(--cream-dark); padding: 12px 16px; text-align: left; font-size: 11px; font-weight: 600; letter-spacing: 0.07em; text-transform: uppercase; color: var(--text-muted); border-bottom: 1px solid var(--border-soft); } .compare-table tbody td { padding: 12px 16px; border-bottom: 1px solid var(--border-soft); vertical-align: top; font-family: 'Source Sans 3', sans-serif; color: var(--text-body); line-height: 1.55; } .compare-table tbody tr:last-child td { border-bottom: none; } .compare-table tbody td:first-child { font-weight: 600; color: var(--text-primary); width: 32%; }
/ COST TABLE / .cost-table { width: 100%; border-collapse: collapse; border: 1px solid var(--border-soft); border-radius: 8px; overflow: hidden; margin: 18px 0 8px; font-size: 15px; } .cost-table thead th { background: var(--cream-dark); padding: 11px 16px; text-align: left; font-size: 11px; font-weight: 600; letter-spacing: 0.07em; text-transform: uppercase; color: var(--text-muted); border-bottom: 1px solid var(--border-soft); } .cost-table tbody td { padding: 11px 16px; border-bottom: 1px solid var(--border-soft); font-family: 'Source Sans 3', sans-serif; color: var(--text-body); line-height: 1.5; } .cost-table tbody tr:last-child td { border-bottom: none; } .cost-table tbody td:first-child { font-weight: 600; color: var(--text-primary); width: 30%; } .cost-table .highlight td { background: var(--green-light); } .cost-table .highlight td:first-child { color: var(--green-dark); } .cost-table .saving { color: var(--green-mid); font-weight: 600; }
.sources-line { font-size: 13px; color: var(--text-muted); margin: 4px 0 24px; font-style: italic; }
/ CTA-A: dark green block / .cta-a { background: var(--green-dark); border-radius: 12px; padding: 28px 28px 30px; margin: 32px 0; color: #fff; } .cta-a .cta-h { font-family: 'Source Sans 3', sans-serif; font-size: 18px; font-weight: 600; color: #fff; margin-bottom: 8px; line-height: 1.4; } .cta-a .cta-s { font-family: 'Source Sans 3', sans-serif; font-size: 15px; color: rgba(255,255,255,.78); margin-bottom: 20px; line-height: 1.6; } .btn-white { display: inline-block; background: #fff; color: var(--green-dark); font-family: 'Source Sans 3', sans-serif; font-size: 15px; font-weight: 600; padding: 11px 22px; border-radius: 6px; text-decoration: none; transition: background 0.15s; } .btn-white:hover { background: #e8f4ee; }
/ CTA-B: light bordered card / .cta-b { border: 1.5px solid var(--green-border); background: #fff; border-radius: 10px; padding: 20px 22px 22px; margin: 24px 0; display: flex; flex-direction: column; gap: 10px; } .cta-b .cta-h { font-family: 'Source Sans 3', sans-serif; font-size: 16px; font-weight: 600; color: var(--text-primary); line-height: 1.4; } .cta-b .cta-s { font-family: 'Source Sans 3', sans-serif; font-size: 14px; color: var(--text-muted); line-height: 1.6; } .btn-green { display: inline-block; background: var(--green-dark); color: #fff; font-family: 'Source Sans 3', sans-serif; font-size: 14px; font-weight: 600; padding: 10px 20px; border-radius: 6px; text-decoration: none; align-self: flex-start; transition: background 0.15s; } .btn-green:hover { background: var(--green-mid); }
/ CTA-C: navigational link / .cta-c { display: flex; align-items: flex-start; gap: 14px; background: var(--cream-dark); border: 1px solid var(--border-soft); border-radius: 8px; padding: 16px 20px; margin: 20px 0; text-decoration: none; transition: border-color 0.15s, background 0.15s; } .cta-c:hover { background: var(--green-light); border-color: var(--green-border); } .cta-c .cta-arrow { font-size: 20px; color: var(--green-mid); line-height: 1; flex-shrink: 0; margin-top: 2px; } .cta-c .rl-label { font-size: 15px; color: var(--green-mid); font-weight: 600; margin-bottom: 4px; font-family: 'Source Sans 3', sans-serif; } .cta-c .rl-desc { font-size: 14px; color: var(--text-muted); font-family: 'Source Sans 3', sans-serif; line-height: 1.5; }
@media (max-width: 600px) { .stat-strip { grid-template-columns: 1fr 1fr; } .compare-table, .cost-table { font-size: 14px; } .compare-table thead th, .compare-table tbody td, .cost-table thead th, .cost-table tbody td { padding: 10px 12px; } } </style> </head> <body> <div class="page-wrap">
<span class="meta-tag">Breast Cancer · Diagnosis</span>
<h1>HER2-Positive vs Triple-Negative Breast Cancer: What Your Pathology Report Is Actually Telling You</h1>
<p class="deck">Your pathology report does more than confirm cancer. It identifies the molecular subtype that determines every treatment decision ahead — and for international patients, it is the document that makes world-class treatment in India both possible and remarkably affordable.</p>
<!-- ANATOMICAL ILLUSTRATION --> <div class="illustration-wrap"> <svg viewBox="0 0 700 280" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="Anatomical diagram comparing receptor status in breast cancer cells at the cellular level. The left panel shows a HER2-positive cancer cell with many HER2 receptor proteins — depicted as green dots — densely covering its outer membrane, far more than a healthy cell would carry. The right panel shows a triple-negative cancer cell with no ER, PR, or HER2 receptors visible on its membrane; only faint dashed stubs indicate the absence of these proteins. Both cells show a central nucleus. The illustration explains why HER2-positive cancers respond to targeted receptor-blocking drugs like trastuzumab, while triple-negative cancers do not — as there are no receptors for these drugs to bind to. This difference drives the treatment approach chosen by oncology teams in India and worldwide."> <defs> <linearGradient id="bgGrad" x1="0" y1="0" x2="0" y2="1"> <stop offset="0%" stop-color="#EDE9DF"/> <stop offset="100%" stop-color="#E4DFCF"/> </linearGradient> </defs> <rect width="700" height="280" fill="url(#bgGrad)"/> <text x="170" y="28" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="12" font-weight="600" fill="#6B6860" letter-spacing="0.08em">HER2-POSITIVE CELL</text> <text x="530" y="28" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="12" font-weight="600" fill="#6B6860" letter-spacing="0.08em">TRIPLE-NEGATIVE CELL</text> <line x1="350" y1="16" x2="350" y2="264" stroke="#DDD9CF" stroke-width="1" stroke-dasharray="5 4"/> <ellipse cx="160" cy="148" rx="44" ry="42" fill="#FDE8D8" stroke="#D07040" stroke-width="1.5"/> <text x="160" y="152" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="11" fill="#A05020">Nucleus</text> <ellipse cx="160" cy="148" rx="90" ry="86" fill="none" stroke="#C09060" stroke-width="2"/> <line x1="160" y1="62" x2="160" y2="48" stroke="#2D7A52" stroke-width="2.5" stroke-linecap="round"/><circle cx="160" cy="45" r="5" fill="#2D7A52"/> <line x1="135" y1="66" x2="126" y2="53" stroke="#2D7A52" stroke-width="2.5" stroke-linecap="round"/><circle cx="123" cy="51" r="5" fill="#2D7A52"/> <line x1="185" y1="66" x2="194" y2="53" stroke="#2D7A52" stroke-width="2.5" stroke-linecap="round"/><circle cx="197" cy="51" r="5" fill="#2D7A52"/> <line x1="70" y1="148" x2="56" y2="148" stroke="#2D7A52" stroke-width="2.5" stroke-linecap="round"/><circle cx="53" cy="148" r="5" fill="#2D7A52"/> <line x1="72" y1="124" x2="58" y2="116" stroke="#2D7A52" stroke-width="2.5" stroke-linecap="round"/><circle cx="55" cy="113" r="5" fill="#2D7A52"/> <line x1="72" y1="172" x2="58" y2="180" stroke="#2D7A52" stroke-width="2.5" stroke-linecap="round"/><circle cx="55" cy="183" r="5" fill="#2D7A52"/> <line x1="250" y1="148" x2="264" y2="148" stroke="#2D7A52" stroke-width="2.5" stroke-linecap="round"/><circle cx="267" cy="148" r="5" fill="#2D7A52"/> <line x1="248" y1="124" x2="262" y2="116" stroke="#2D7A52" stroke-width="2.5" stroke-linecap="round"/><circle cx="265" cy="113" r="5" fill="#2D7A52"/> <line x1="248" y1="172" x2="262" y2="180" stroke="#2D7A52" stroke-width="2.5" stroke-linecap="round"/><circle cx="265" cy="183" r="5" fill="#2D7A52"/> <line x1="160" y1="234" x2="160" y2="248" stroke="#2D7A52" stroke-width="2.5" stroke-linecap="round"/><circle cx="160" cy="251" r="5" fill="#2D7A52"/> <line x1="135" y1="230" x2="126" y2="243" stroke="#2D7A52" stroke-width="2.5" stroke-linecap="round"/><circle cx="123" cy="246" r="5" fill="#2D7A52"/> <line x1="185" y1="230" x2="194" y2="243" stroke="#2D7A52" stroke-width="2.5" stroke-linecap="round"/><circle cx="197" cy="246" r="5" fill="#2D7A52"/> <rect x="78" y="258" width="165" height="18" rx="4" fill="#EAF4EE" stroke="#C2DFCC" stroke-width="1"/> <text x="160" y="271" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="11" fill="#1B5E3B" font-weight="600">● HER2 receptors (overexpressed)</text> <ellipse cx="530" cy="148" rx="44" ry="42" fill="#F9E8E8" stroke="#B04040" stroke-width="1.5"/> <text x="530" y="152" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="11" fill="#802020">Nucleus</text> <ellipse cx="530" cy="148" rx="90" ry="86" fill="none" stroke="#C09090" stroke-width="2"/> <line x1="530" y1="62" x2="530" y2="52" stroke="#BBBBBB" stroke-width="1.5" stroke-linecap="round" stroke-dasharray="3 3"/> <line x1="440" y1="148" x2="430" y2="148" stroke="#BBBBBB" stroke-width="1.5" stroke-linecap="round" stroke-dasharray="3 3"/> <line x1="620" y1="148" x2="630" y2="148" stroke="#BBBBBB" stroke-width="1.5" stroke-linecap="round" stroke-dasharray="3 3"/> <line x1="530" y1="234" x2="530" y2="244" stroke="#BBBBBB" stroke-width="1.5" stroke-linecap="round" stroke-dasharray="3 3"/> <text x="530" y="120" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="22" fill="#D08080" opacity="0.35">✕</text> <rect x="376" y="258" width="308" height="18" rx="4" fill="#FDF2F2" stroke="#E8BABA" stroke-width="1"/> <text x="530" y="271" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="11" fill="#B04040" font-weight="600">No ER, PR, or HER2 receptors detected</text> </svg> <p class="img-caption">Receptor status at the cellular level. HER2-positive cells (left) carry excess HER2 proteins on their membrane — the target for drugs like trastuzumab. Triple-negative cells (right) carry none of the three receptors, which is why hormonal and HER2-targeted therapies cannot work against them. India's leading cancer centres test for all three receptors as a standard first step for every newly diagnosed patient.</p> </div>
<!-- TOC --> <div class="toc-box"> <div class="toc-label">What's in this guide</div> <ol> <li><a href="#what-pathology-tells-you">What your pathology report is actually saying</a></li> <li><a href="#her2-explained">HER2-positive breast cancer — and how India treats it</a></li> <li><a href="#tnbc-explained">Triple-negative breast cancer — and the new therapies available</a></li> <li><a href="#treatment-differences">How their treatments differ — side by side</a></li> <li><a href="#cost-india">What treatment costs in India vs the US and UK</a></li> <li><a href="#next-steps">How to arrange treatment in India from your country</a></li> </ol> </div>
<div class="prose">
<!-- ─── SECTION 1 ─── --> <h2 id="what-pathology-tells-you">What your pathology report is actually saying</h2>
<p>When you receive a breast cancer diagnosis, the biopsy does not simply confirm cancer is present. It tells your oncologist what <em>kind</em> of cancer it is — and that distinction drives every treatment decision from that point forward.</p>
<p>The report tests your tumour for three specific proteins: the oestrogen receptor (ER), the progesterone receptor (PR), and the HER2 protein. Think of these as locks on the surface of a cancer cell.</p>
<p>If a lock exists, a drug can be engineered to fit it — blocking the growth signal, or delivering a toxin directly into that cell. Your subtype is a map of which locks your tumour carries.</p>
<div class="quick-box"> <div class="qa-label">Quick answer</div> <div class="qa-question">What does it mean if I'm HER2-positive or triple-negative?</div> <div class="qa-answer">HER2-positive means your tumour overproduces the HER2 growth protein — now one of the <strong>most treatable subtypes</strong> due to drugs like trastuzumab. Triple-negative means the tumour lacks all three receptors, making hormonal and HER2-targeted therapies ineffective. Both subtypes are treated at India's leading cancer centres using the same protocols followed in the US, UK, and Germany — at a fraction of the cost.</div> </div>
<p>About <strong>70% of breast cancers</strong> are hormone receptor-positive, responding to long-term endocrine therapy. The remaining 30% split between HER2-positive and triple-negative.</p>
<p>These are the two subtypes that most often come as a shock — not because they are rarer, but because they require more complex, expensive treatment. That is precisely where India's oncology infrastructure makes the biggest difference for international patients.</p>
<!-- CTA 1 --> <div class="cta-b"> <p class="cta-h">Not sure what your receptor status means for your treatment plan?</p> <p class="cta-s">Share your biopsy report with our oncology coordinators in India. We will explain your subtype, what it means for your treatment, and outline your options — at no charge, within 24 hours.</p> <a href="https://gafhealthcare.in/contact" class="btn-green">Get Free Pathology Review →</a> </div>
<!-- ─── SECTION 2 ─── --> <h2 id="her2-explained">HER2-positive breast cancer — and how India treats it</h2>
<p>HER2 stands for Human Epidermal Growth Factor Receptor 2. In a healthy breast cell, it plays a normal regulatory role — sitting on the surface, helping coordinate cell growth.</p>
<p>In HER2-positive cancer, the gene coding for this protein goes into overdrive. The cell produces far more HER2 receptors than it should, each one sending a signal to divide.</p>
<p>Around <strong>20% of breast cancers</strong> are HER2-positive. Before targeted therapy existed, this subtype was considered a poor prognosis — faster growing, harder to control with standard chemotherapy.</p>
<p>Then came trastuzumab — brand name Herceptin. The first drug engineered to attach directly to the HER2 receptor and shut down the growth signal. The change in outcomes was extraordinary.</p>
<div class="stat-strip"> <div class="stat-cell"><div class="stat-label">Share of breast cancers</div><div class="stat-val">20%</div></div> <div class="stat-cell"><div class="stat-label">5-year survival (stage I–II)</div><div class="stat-val">>95%</div></div> <div class="stat-cell"><div class="stat-label">Trastuzumab duration</div><div class="stat-val">12 mo</div></div> </div>
<p>Patients with early-stage HER2-positive disease who complete surgery, chemotherapy, and twelve months of trastuzumab now see five-year survival rates exceeding 95% at stage I and II.</p>
<p>Newer agents — T-DM1 and trastuzumab deruxtecan (T-DXd) — have extended the benefit further into residual and metastatic disease. India's top cancer centres administer all of these, in full.</p>
<div class="callout-green"> <div class="callout-label">Why India makes a difference for HER2-positive patients</div> <p>Trastuzumab costs $6,000–$8,000 per cycle in the United States. In India, <strong>biosimilar trastuzumab</strong> — approved by India's Central Drugs Standard Control Organisation and clinically equivalent to the original Herceptin — is administered at Apollo, Fortis, and Medanta at approximately $300–$500 per cycle. Over twelve months of treatment, that difference is not marginal. It is the difference between treatment and no treatment for most patients coming from Africa, the Middle East, and South Asia.</p> </div>
<p>The protocol your Indian oncologist follows is not adapted or simplified. It is the same trastuzumab-based regimen — TCHP or AC-TH — used at Memorial Sloan Kettering and the Royal Marsden. The drug, the dose, the schedule, and the monitoring are identical. The cost is not.</p>
<!-- CTA 2 --> <div class="cta-b"> <p class="cta-h">Want an itemised cost estimate for HER2-positive treatment in India?</p> <p class="cta-s">Share your staging report. We will send detailed figures — surgery, chemotherapy cycles, trastuzumab biosimilar pricing, and hospital stay — from 2–3 shortlisted hospitals. No obligation.</p> <a href="https://gafhealthcare.in/contact" class="btn-green">Request My Cost Estimate →</a> </div>
<!-- ─── SECTION 3 ─── --> <h2 id="tnbc-explained">Triple-negative breast cancer — and the new therapies available in India</h2>
<p>Triple-negative breast cancer — TNBC — gets its name from what it <em>lacks</em>. The tumour tests negative for oestrogen receptors, progesterone receptors, and HER2 overexpression.</p>
<p>That absence of targetable proteins is what makes it more complex. You cannot block a receptor that is not there. Hormonal therapies do not work. HER2-targeted drugs do not work either.</p>
<p>TNBC represents roughly <strong>15 to 20% of all breast cancers</strong>. It accounts for a disproportionate share of breast cancer deaths — historically, because chemotherapy was the only tool available.</p>
<p>TNBC also grows more quickly and has a higher early recurrence risk. The first three years after treatment are the critical window — which is why getting the right treatment, from a high-volume centre, matters more here than in any other subtype.</p>
<div class="quick-box"> <div class="qa-label">Quick answer</div> <div class="qa-question">Is triple-negative breast cancer treatable in India?</div> <div class="qa-answer">Yes — and with the same regimens used at leading Western centres. India's top hospitals administer full pembrolizumab-based immunotherapy for eligible TNBC patients, BRCA-guided PARP inhibitors, and the KEYNOTE-522 protocol for early high-risk disease. <strong>Pathological complete response</strong> — elimination of all detectable cancer before surgery — is achieved in roughly 30–40% of TNBC patients on modern regimens, with excellent long-term outcomes in that group.</div> </div>
<p>A significant proportion of TNBC tumours express PD-L1, a protein that helps cancer cells hide from the immune system. Pembrolizumab blocks this evasion — and has demonstrated improved event-free survival in the KEYNOTE-522 trial for early high-risk TNBC.</p>
<p>BRCA mutations are found in around 20% of TNBC patients. PARP inhibitors like olaparib exploit this vulnerability directly. Both pembrolizumab and olaparib are available at accredited Indian cancer centres.</p>
<div class="callout-red"> <div class="callout-label">A note for women from sub-Saharan Africa and South Asia</div> <p>TNBC is significantly more prevalent in women of West and Central African ancestry — some studies suggest it accounts for up to 35–40% of breast cancers in Nigerian and Ghanaian women, compared to 15% in European populations. Women from India's neighbouring countries — Bangladesh, Nepal, Sri Lanka — also show higher TNBC rates at diagnosis. For these patients, accessing a high-volume centre quickly is not optional. It is clinically critical. India offers that access at a cost that is realistic.</p> </div>
<!-- ─── SECTION 4 ─── --> <h2 id="treatment-differences">How their treatments differ — side by side</h2>
<p>The two subtypes require fundamentally different systemic treatment. The surgery options are similar. The drugs that wrap around the surgery are not.</p>
<table class="compare-table"> <thead> <tr><th>Factor</th><th>HER2-Positive</th><th>Triple-Negative</th></tr> </thead> <tbody> <tr> <td>Main systemic treatment</td> <td>Chemotherapy + trastuzumab (± pertuzumab)</td> <td>Chemotherapy ± immunotherapy (pembrolizumab)</td> </tr> <tr> <td>Hormonal therapy</td> <td>Only if also ER-positive (dual positive)</td> <td>Not applicable — no receptors present</td> </tr> <tr> <td>Neoadjuvant approach</td> <td>Standard for most — improves surgical options, gauges response</td> <td>Standard for high-risk — pCR rate is prognostically critical</td> </tr> <tr> <td>If residual cancer at surgery</td> <td>Switch to T-DM1 adjuvant therapy</td> <td>Consider capecitabine or pembrolizumab continuation</td> </tr> <tr> <td>BRCA testing relevance</td> <td>Informs bilateral mastectomy decision</td> <td>Higher BRCA prevalence — affects PARP inhibitor eligibility</td> </tr> <tr> <td>Available in India</td> <td>Full TCHP / AC-TH protocol, biosimilar trastuzumab, T-DM1</td> <td>Full KEYNOTE-522 protocol, pembrolizumab, olaparib, capecitabine</td> </tr> </tbody> </table>
<p>Both subtypes are treated surgically with either lumpectomy or mastectomy — depending on tumour size, multifocality, and patient preference. Both approaches carry equivalent long-term survival for eligible patients.</p>
<p>India's multidisciplinary tumour boards at Apollo, Fortis Memorial, Medanta, and Tata Memorial Hospital review each case collectively — surgical oncologist, medical oncologist, radiation oncologist, pathologist, and radiologist together. This is the same standard of care as a major Western cancer centre.</p>
<!-- CTA 3 --> <a href="https://gafhealthcare.in/treatments/breast-cancer-treatment" class="cta-c"> <div class="cta-arrow">→</div> <div> <div class="rl-label">Full Breast Cancer Treatment Guide — GAF Healthcare</div> <div class="rl-desc">All treatment pathways explained: surgery options, chemotherapy, targeted therapy, radiation, recovery timelines, and a full cost comparison for international patients seeking treatment in India.</div> </div> </a>
<!-- ─── SECTION 5 ─── --> <h2 id="cost-india">What treatment costs in India vs the US and UK</h2>
<p>The cost difference is not a small discount. For patients coming from Zambia, Ghana, Kenya, Nigeria, or the Gulf states, it is often the difference between receiving world-class treatment and receiving no treatment at all.</p>
<p>India's cost advantage comes from three structural factors: lower institutional overheads, government price controls on essential cancer drugs, and the wide availability of biosimilar biologics that are identical in clinical outcome but manufactured at Indian prices.</p>
<table class="cost-table"> <thead> <tr><th>Treatment element</th><th>USA</th><th>UK</th><th class="saving">India</th></tr> </thead> <tbody> <tr> <td>Full HER2+ treatment course (surgery + 12 mo trastuzumab + chemo)</td> <td>$180,000–$350,000</td> <td>£60,000–£110,000</td> <td class="saving">$12,000–$22,000</td> </tr> <tr class="highlight"> <td>Trastuzumab (biosimilar, per cycle)</td> <td>$6,000–$8,000</td> <td>£3,000–£5,000</td> <td class="saving">$300–$500</td> </tr> <tr> <td>Full TNBC treatment (neoadjuvant chemo + surgery + pembrolizumab)</td> <td>$200,000–$400,000</td> <td>£70,000–£130,000</td> <td class="saving">$14,000–$28,000</td> </tr> <tr class="highlight"> <td>Mastectomy with immediate reconstruction</td> <td>$40,000–$80,000</td> <td>£18,000–£35,000</td> <td class="saving">$5,000–$9,000</td> </tr> <tr> <td>PSMA PET-CT or advanced staging scan</td> <td>$4,000–$7,000</td> <td>£2,500–£4,000</td> <td class="saving">$400–$700</td> </tr> </tbody> </table>
<p class="sources-line">Cost ranges based on GAF Healthcare hospital network data, 2025–2026. US figures from FAIR Health. UK figures from NHS reference costs and private sector data.</p>
<p>The hospitals delivering these prices are not budget facilities. Apollo Hospitals performs over 1,200 oncology surgeries per month across its network. Tata Memorial Hospital in Mumbai is ranked among Asia's top five cancer centres by volume and research output. Medanta — The Medicity's oncology division has a dedicated tumour board that sits weekly for breast cancer alone.</p>
<p class="impact">"The same drug. The same protocol. The same staging scan. A fraction of the cost. That is not a compromise — that is what India's oncology infrastructure actually delivers."</p>
<p>GAF Healthcare coordinates the full treatment pathway — from submitting your pathology report for oncologist review, to hospital shortlisting, visa support, treatment scheduling, and medical record transfer when you return home.</p>
<!-- CTA 4 --> <div class="cta-a"> <p class="cta-h">Concerned about treatment cost? Get a real number for your specific case.</p> <p class="cta-s">Share your biopsy report, staging scans, and diagnosis details. Our team will send itemised cost estimates from 2–3 shortlisted Indian hospitals — at no charge, within 24 hours.</p> <a href="https://gafhealthcare.in/contact" class="btn-white">Get My Cost Estimate →</a> </div>
<!-- ─── SECTION 6 ─── --> <h2 id="next-steps">How to arrange treatment in India from your country</h2>
<p>The process is more straightforward than most patients expect. The first step happens before you book any travel.</p>
<p><strong>Submit your pathology report.</strong> Your ER, PR, and HER2 receptor status, your Gleason grade equivalent, and your staging scans are what the oncology team needs to review your case and confirm your treatment plan. You do not need to be physically present in India for this step.</p>
<p><strong>Request a second opinion if anything is borderline.</strong> HER2 testing in particular has a margin of error. If your result was IHC 2+ and FISH testing was not performed, ask about it. A high-volume Indian centre will confirm or revise the result as part of the intake process.</p>
<p><strong>Ask about BRCA testing</strong> if you have TNBC, a family history of breast or ovarian cancer, or were diagnosed under 50. The result affects both your surgical options and your eligibility for PARP inhibitors — drugs that are available in India and that many patients from lower-income countries cannot access at home.</p>
<p><strong>Plan the treatment sequence with your coordinator.</strong> Many patients from Africa and the Gulf complete the surgical episode and the first cycle or two of systemic therapy in India, then transition back to a local oncologist for continuing chemotherapy cycles — with the Indian team managing the treatment plan documentation and remote oversight. GAF Healthcare facilitates this handoff specifically.</p>
<p><strong>Allow two to three weeks for the core surgical episode.</strong> Most breast cancer surgeries are one to three nights in hospital. Recovery to air-travel fitness takes ten to fourteen days for lumpectomy patients, and three to four weeks for mastectomy with reconstruction. Chemotherapy continues as outpatient infusions — in India or at home.</p>
<p>None of this is as complicated as it sounds when you have a coordinator who has done it hundreds of times before. The barrier is not logistical. It is informational — knowing where to start.</p>
<!-- CTA 5 --> <div class="cta-a"> <p class="cta-h">Ready to explore breast cancer treatment in India?</p> <p class="cta-s">Share your diagnosis details with our medical team. We will review your subtype, recommend the right hospital and oncologist, outline the full treatment sequence, and give you honest cost figures — at no charge, no obligation, within 24 hours.</p> <a href="https://gafhealthcare.in/contact" class="btn-white">Start My Free Consultation →</a> </div>
<a href="https://gafhealthcare.in/treatments/breast-cancer-treatment" class="cta-c"> <div class="cta-arrow">→</div> <div> <div class="rl-label">Full Breast Cancer Treatment Guide — GAF Healthcare</div> <div class="rl-desc">Surgery, chemotherapy, targeted therapy, radiation, costs, and recovery explained in full. Everything international patients need to plan treatment in India.</div> </div> </a>
</div> </div> </body> </html>